Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Promune + Chemotherapy in Advanced NSCLC
NCT00070629Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2003
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 3
01
Overview
A Phase 2 trial of agatolimod in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started May 2003; status: completed.
02
Drugs
agatolimod
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00070629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070629.